Literature DB >> 8755927

Allelic loss is frequent in tuberous sclerosis kidney lesions but rare in brain lesions.

E P Henske1, B W Scheithauer, M P Short, R Wollmann, J Nahmias, N Hornigold, M van Slegtenhorst, C T Welsh, D J Kwiatkowski.   

Abstract

Tuberous sclerosis (TSC) is an autosomal dominant disorder characterized by seizures, mental retardation, and hamartomatous lesions. Although hamartomas can occur in almost any organ, they are most common in the brain, kidney, heart, and skin. Allelic loss or loss of heterozygosity (LOH) in TSC lesions has previously been reported on chromosomes 16p13 and 9q34, the locations of the TSC2 and TSC1 genes, respectively, suggesting that the TSC genes act as tumor-suppressor genes. In our study, 87 lesions from 47 TSC patients were analyzed for LOH in the TSC1 and TSC2 chromosomal regions. Three findings resulted from this analysis. First, we confirmed that the TSC1 critical region is distal to D9S149. Second, we found LOH more frequently on chromosome 16p13 than on 9q34. Of the 28 patients with angiomyolipomas or rhabdomyomas, 16p13 LOH was detected in lesions from 12 (57%) of 21 informative patients, while 9q34 LOH was detected in lesions from only 1 patient (4%). This could indicate that TSC2 tumors are more likely than TSC1 tumors to require surgical resection or that TSC2 is more common than TSC1 in our patient population. It is also possible that small regions of 9q34 LOH were missed. Lastly, LOH was found in 56% of renal angiomyolipomas and cardiac rhabdomyormas but in only 4% of TSC brain lesions. This suggests that brain lesions can result from different pathogenic mechanisms than kidney and heart lesions.

Entities:  

Mesh:

Year:  1996        PMID: 8755927      PMCID: PMC1914733     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  23 in total

1.  Construction of a GT polymorphism map of human 9q.

Authors:  D J Kwiatkowski; E P Henske; K Weimer; L Ozelius; J F Gusella; J Haines
Journal:  Genomics       Date:  1992-02       Impact factor: 5.736

2.  A second-generation linkage map of the human genome.

Authors:  J Weissenbach; G Gyapay; C Dib; A Vignal; J Morissette; P Millasseau; G Vaysseix; M Lathrop
Journal:  Nature       Date:  1992-10-29       Impact factor: 49.962

3.  Evidence for genetic heterogeneity in tuberous sclerosis: one locus on chromosome 9 and at least one locus elsewhere.

Authors:  H Northrup; D J Kwiatkowski; E S Roach; W B Dobyns; R A Lewis; G E Herman; E Rodriguez; S P Daiger; S H Blanton
Journal:  Am J Hum Genet       Date:  1992-10       Impact factor: 11.025

4.  Phenotypes of the tuberous sclerosis complex with a revision of diagnostic criteria.

Authors:  M R Gomez
Journal:  Ann N Y Acad Sci       Date:  1991       Impact factor: 5.691

5.  A 5.4-Mb continuous pulsed-field gel electrophoresis map of human 9q34.1 between ABL and D9S114, including the tuberous sclerosis (TSC1) region.

Authors:  E P Henske; D J Kwiatkowski
Journal:  Genomics       Date:  1995-07-01       Impact factor: 5.736

6.  Genetic aspects of tuberous sclerosis in the west of Scotland.

Authors:  J R Sampson; S J Scahill; J B Stephenson; L Mann; J M Connor
Journal:  J Med Genet       Date:  1989-01       Impact factor: 6.318

7.  A high-resolution linkage map of human 9q34.1.

Authors:  E P Henske; L Ozelius; J F Gusella; J L Haines; D J Kwiatkowski
Journal:  Genomics       Date:  1993-09       Impact factor: 5.736

8.  Report and abstracts of the Fourth International Workshop on Human Chromosome 3 Mapping.

Authors:  S L Naylor; C H Buys; B Carritt
Journal:  Cytogenet Cell Genet       Date:  1994

9.  5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers.

Authors:  A Merlo; J G Herman; L Mao; D J Lee; E Gabrielson; P C Burger; S B Baylin; D Sidransky
Journal:  Nat Med       Date:  1995-07       Impact factor: 53.440

10.  Apparent preferential loss of heterozygosity at TSC2 over TSC1 chromosomal region in tuberous sclerosis hamartomas.

Authors:  C Carbonara; L Longa; E Grosso; G Mazzucco; C Borrone; M L Garrè; M Brisigotti; G Filippi; A Scabar; A Giannotti; P Falzoni; G Monga; G Garini; M Gabrielli; P Riegler; C Danesino; M Ruggieri; G Magro; N Migone
Journal:  Genes Chromosomes Cancer       Date:  1996-01       Impact factor: 5.006

View more
  93 in total

1.  Complete inactivation of the TSC2 gene leads to formation of hamartomas.

Authors:  K S Au; A A Hebert; E S Roach; H Northrup
Journal:  Am J Hum Genet       Date:  1999-12       Impact factor: 11.025

2.  Mutational spectrum of the TSC1 gene in a cohort of 225 tuberous sclerosis complex patients: no evidence for genotype-phenotype correlation.

Authors:  M van Slegtenhorst; S Verhoef; A Tempelaars; L Bakker; Q Wang; M Wessels; R Bakker; M Nellist; D Lindhout; D Halley; A van den Ouweland
Journal:  J Med Genet       Date:  1999-04       Impact factor: 6.318

3.  Biallelic TSC gene inactivation in tuberous sclerosis complex.

Authors:  Peter B Crino; Eleonora Aronica; Gordon Baltuch; Katherine L Nathanson
Journal:  Neurology       Date:  2010-05-25       Impact factor: 9.910

4.  Diaschisis: An Old Concept Brought to New Life.

Authors:  R Michelle Saré
Journal:  J Neurosci       Date:  2016-01-27       Impact factor: 6.167

5.  A defect in protein farnesylation suppresses a loss of Schizosaccharomyces pombe tsc2+, a homolog of the human gene predisposing to tuberous sclerosis complex.

Authors:  Yukiko Nakase; Keiko Fukuda; Yuji Chikashige; Chihiro Tsutsumi; Daisuke Morita; Shinpei Kawamoto; Mari Ohnuki; Yasushi Hiraoka; Tomohiro Matsumoto
Journal:  Genetics       Date:  2006-04-19       Impact factor: 4.562

6.  Characterisation of TSC1 promoter deletions in tuberous sclerosis complex patients.

Authors:  Ans M W van den Ouweland; Peter Elfferich; Bernard A Zonnenberg; Willem F Arts; Tjitske Kleefstra; Mark D Nellist; Jose M Millan; Caroline Withagen-Hermans; Anneke J A Maat-Kievit; Dicky J J Halley
Journal:  Eur J Hum Genet       Date:  2010-09-29       Impact factor: 4.246

7.  The role of the Birt-Hogg-Dubé protein in mTOR activation and renal tumorigenesis.

Authors:  T R Hartman; E Nicolas; A Klein-Szanto; T Al-Saleem; T P Cash; M C Simon; E P Henske
Journal:  Oncogene       Date:  2009-02-23       Impact factor: 9.867

Review 8.  Tuberous sclerosis complex: a brave new world?

Authors:  Kevin C Ess
Journal:  Curr Opin Neurol       Date:  2010-04       Impact factor: 5.710

9.  The methylation of the TSC2 promoter underlies the abnormal growth of TSC2 angiomyolipoma-derived smooth muscle cells.

Authors:  Elena Lesma; Silvia Maria Sirchia; Silvia Ancona; Stephana Carelli; Silvano Bosari; Filippo Ghelma; Emanuele Montanari; Anna Maria Di Giulio; Alfredo Gorio
Journal:  Am J Pathol       Date:  2009-05-14       Impact factor: 4.307

Review 10.  Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.

Authors:  Jeffrey P MacKeigan; Darcy A Krueger
Journal:  Neuro Oncol       Date:  2015-08-19       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.